Subtypes of breast cancer that represent the two major types of epithelial cells in the breast (luminal and basal) carry distinct histopathologic profiles. Breast cancers of the basallike subtype, which include the majority of hereditary breast cancers due to mutations in the breast cancer susceptibility gene 1 (BRCA1), frequently assume triple-negative status, i.e., they lack expression of estrogen receptor-A and progesterone receptor, and lack overexpression or amplification of the HER2/NEU oncogene. Defects in DNA damage response pathways result in genome instability and lead to carcinogenesis, but may also be exploited for therapeutic purposes. We analyzed repair of oxidative DNA damage by the base-excision repair (BER) pathway, which when aberrant leads to genomic instability and breast carcinogenesis, in cell lines that represent the different subtypes of breast cancer and in the presence of BRCA1 deficiency. We found that basal-like and BRCA1-mutated breast cancer cells were defective in BER of oxidative DNA damage, and that this defect conferred sensitivity to inhibition of poly(ADP-ribose) polymerase, a DNA repair enzyme. The defect may be attributed, at least in part, to a novel role for BRCA1 in the BER pathway. Overall, these data offer preventive, prognostic, and therapeutic usefulness. [Cancer Res 2009;69(8):3589-96] 
Introduction
Breast cancer is a heterogeneous disease that consists of different molecular and pathologic subtypes. The subtypes represent the two major types of epithelial cells in the breast (luminal and basal) and were first identified by gene expression profiling (1) . Each subtype carries a distinct histopathologic profile. Breast cancers of the basal-like subtype frequently assume triplenegative status, i.e., they lack expression of estrogen receptor-a and progesterone receptor, and lack overexpression or amplification of the HER2/NEU oncogene (1-4). Furthermore, they express genes linked to proliferation and often associate with a more aggressive clinical course, including poor clinical outcome, recurrence, and metastasis (1, 2, (4) (5) (6) (7) (8) (9) (10) (11) .
Hereditary breast cancers due to mutations in the breast cancer susceptibility gene 1 (BRCA1) are primarily of the basal-like subtype and also tend to be triple-negative (11) (12) (13) . They share similar gene expression patterns, morphologic characteristics, immunohistochemical profiles, and pathologic features with sporadic basal-like breast cancers, including high histologic grade, high mitotic index, overexpression of epidermal growth factor receptor, mutations in p53, and cytogenetic abnormalities (14) .
The triple-negative status of many basal-like and BRCA1-mutated breast cancers make these tumors particularly challenging to treat because targeted agents against estrogen receptor and HER2/NEU are ineffective in this setting. Therefore, cytotoxic chemotherapy and radiation remain the only therapeutic options. Unfortunately, despite response to conventional regimens, these cancers retain a poor prognosis (15) , suggesting the need for improved systemic treatments.
Defects in DNA damage response pathways result in genome instability and lead to carcinogenesis, but may be exploited for therapeutic purposes. For example, BRCA1 encodes a tumor suppressor that functions in multiple DNA damage response pathways, including DNA double-strand break repair (i.e., homologous recombination and nonhomologous end-joining) and nucleotide excision repair (16, 17) , and thereby maintains genomic stability and prevents carcinogenesis. Likewise, BRCA1-deficient cells, due to defects in DNA repair, are highly sensitive to drugs, such as mitomycin C and cisplatin, that induce interstrand and intrastrand DNA crosslinks, stalled replication forks, and in turn, DNA double-strand breaks. Recently, BRCA1-deficient and BRCA2-deficient cells have been shown to exhibit sensitivity to poly(ADPribose) polymerase (PARP) inhibitors, also thought to be due to their DNA repair defects (18, 19) . PARP-1 is one of a family of enzymes that synthesize poly(ADP-ribose) and is known to function in base-excision repair (BER) by recruiting essential mediators to single-strand break intermediates (20) . A better understanding of DNA damage response pathways in subtypes of breast cancer may result in therapeutic benefit.
Oxidative DNA damage (ODD) constitutes the majority of DNA damage in human cells due to reactive oxygen species, which are genotoxic agents generated endogenously by metabolism and other biological processes. ODD typically occurs as single-base alterations and undergoes repair by the BER pathway. When left unrepaired, ODD results in mutagenesis. For example, the most common ODD lesion, 8-oxoguanine, can mispair and result in GC ! TA transversions. Alternatively, ODD converts to single-or double-stranded breaks and results in genomic instability. Overall, these events contribute to the initiation, progression, and maintenance of breast cancer.
Given the many phenotypic similarities between basal-like and BRCA1-mutated breast cancers, we hypothesized that they may also share defects in maintaining genomic stability via aberrant regulation of ODD. Little is known about the regulation of ODD among the different subtypes of breast cancer, but understanding these mechanisms may be important for developing more targeted treatment strategies, such as inhibition of PARP or other DNA repair proteins. In this study, we analyzed the ability to repair ODD by BER in the different subtypes of breast cancer and in the presence of BRCA1 deficiency and discovered that basal-like and BRCA1-mutated breast cancer cells were both defective in repairing ODD. We also found that selective attenuation of BER by knockdown of 8-oxoguanine DNA glycosylase (hOGG1) conferred sensitivity to the inhibition of PARP, an important DNA repair enzyme. Taken together, our results showed that both BRCA1-mutated and basal-like breast cancer cells were defective in BER, and that this defect conferred sensitivity to PARP inhibition, suggesting novel approaches for the treatment of triple-negative breast cancer.
Materials and Methods
Cell lines. BRCA1-mutated cell lines included HCC1937, MDAMB436, SUM149PT, and SUM1315MO2. Basal-like cell lines included BT549, HCC38, HCC1143, HCC1500, HCC1806, hs578T, MDAMB231, and MDAMB468. Luminal cell lines included BT474, MCF7, MDAMB361, and T47D. Normal-like cell lines included MCF10A and MCF12A. SUM149PT and SUM1315MO2 were obtained from and cultured as recommended by Asterand plc. All other cell lines were cultured as recommended by American Type Culture Collection. BRCA1
+/+ and BRCA1 À/À murine mammary epithelial cells (MMEC) have been previously described (21) .
To generate stable isogenic cell lines with altered expression of hOGG1, MCF7 cells were transduced with hOGG1 short hairpin RNA (shRNA) or nontargeting control shRNA and selected with 1 Ag/mL of puromycin. All cell lines were maintained at 37jC and 5% CO 2 . Chemicals and reagents. Chemicals included hydrogen peroxide (H 2 O 2 ; Fisher Scientific), methyl methanesulfonate (MMS; Sigma-Aldrich), and 1,5-isoquinolinediol (IQD; Calbiochem). The wild-type BRCA1 construct was kindly provided by Simon Powell (Memorial Sloan-Kettering Cancer Center, New York, NY) and has previously been described (22) . shRNA to BRCA1 (5 ¶-TGCCAAAGTAGCTAATGTA-3 ¶), two different shRNA to hOGG1 (A, 5 ¶-GTATGGACACTGACTCAGA-3 ¶; B, 5 ¶-GTACTTCCAGCTAGATGTT-3 ¶), and nontargeting control shRNA (5 ¶-GGCTAGACCTCCAAGATCA-3 ¶ and 5 ¶-GGAGATCAGCCATTAATAT-3 ¶) were cloned into pSUPER.retro.puro (Oligoengine) according to the manufacturer's instructions.
Real-time quantitative PCR. Total RNA was extracted using the RNeasy mini kit (Qiagen). Reverse transcription was carried out using the Firststrand cDNA Synthesis Kit (GE Healthcare). The real-time PCR reaction mix contained 10 ng of template cDNA, TaqMan Universal PCR master mix (Applied Biosystems), 900 nmol/L of hOGG1 primer ( forward, 5 ¶-AATTCCAAGGTGTGCGACTG-3 ¶; reverse, 5 ¶-CGATGTTGTTGTTGGAG-GAAC-3 ¶), 250 nmol/L of TaqMan hOGG1 probe (5 ¶-CGACAAGACCCCATC-GAATGCCTTTTC-3 ¶), and 50 nmol/L of TaqMan rRNA Control Reagents/ VIC Probe (GE Healthcare). Each reaction was dispensed in quadruplicate. The cycling conditions included 50jC for 2 min, 95jC for 10 min, and 40 cycles of 95jC for 30 s and 60jC for 1 min. The comparative threshold method (23) determined relative RNA expression.
Western blot. Nuclear lysates were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific) according to the manufacturer's instructions, resolved by SDS-PAGE, transferred to polyvinylidene difluoride membrane, blocked, and probed with the appropriate antibody. Antibodies included anti-BRCA1 (Calbiochem) and anti-TATA binding protein (Abcam). Protein was detected by horseradish peroxidaseconjugated secondary antibody and ECL detection system (GE Healthcare).
MTT assay. Cells were seeded in 96-well plates, allowed to adhere, and treated in quadruplicate with vehicle-control or increasing concentrations of drug. After the indicated period of time, MTT (Sigma-Aldrich) was added to each well and incubated until formation of formazan crystals by the mitochondria of living cells; formazan crystals were then made soluble with DMSO. Absorbance was determined at 570 nm by spectrophotometry. Sensitivity was expressed as a percentage of vehicle-control-treated cells by dividing the absorbance of each treated well by the mean of the vehiclecontrol wells. IC 50 defines the concentration at which 50% of the cells were inhibited following treatment.
Alkaline comet assay. The alkaline comet assay was modified for the detection of oxidized bases using a bacterial repair endonuclease and carried out as previously described (24, 25) . Briefly, following cell lysis of logarithmically growing cells, DNA was subjected to FPG enzyme (i.e., an ODD-specific endonuclease), denatured under alkaline conditions, electrophoresed to resolve fragmented DNA from intact DNA, and then visualized with SYBR green by fluorescent microscopy under a 20Â objective as a comet in shape. Comet heads indicate intact DNA; FPG-induced comet tails indicate ODD. ODD was calculated as the percentage of DNA in the tail for FPGtreated (+FPG) less control (ÀFPG) samples using CometScore software (TriTek Corporation). More than 200 cells for each sample were scored.
BER assay. Human-specific adenovirus containing the green fluorescent protein (GFP) coding sequence (ad-GFP; Clontech) was incubated with 5 Amol/L of methylene blue and exposed to 2 mW/cm 2 of visible light for 0 (undamaged control) or 1 min to induce ODD using the photodynamic setup ( Supplementary Fig. S1A ). Cells were then infected with undamagedcontrol or damaged ad-GFP. Photodynamic treatment and infection was carried out in the dark under blue light. For fluorescent microscopy, cells were visualized under a 10Â objective. For fluorescent plate reading, cells were collected, washed, resuspended in PBS, and counted. Equal cell numbers were dispensed in quadruplicate to black 96-well plates and read at Ex475/Em505 using a fluorescent plate reader. GFP expression was calculated following log transformation of the fluorescent readings as a ratio of damaged to undamaged control. The confidence interval was computed based on a t distribution using the logged values.
Statistical analysis. Unless otherwise noted, data were expressed as mean F SE. P values were determined using the two-tailed Student's t test. Relationships between variables were determined using linear regression analysis and evaluated using the coefficient of determination (r 2 ). Correlations were determined by calculating the Pearson correlation coefficient (r). 
Results
Sensitivity to ODD among subtypes of breast cancer. To evaluate the response to ODD among the different subtypes of breast cancer and in BRCA1-mutated breast cancers, we first identified a panel of breast cell lines characteristic of the normal breast (i.e., normal-like; MCF10A and MCF12A), as well as luminal (BT474, MCF7, MDAMB361, and T47D), basal-like (BT549, HCC38, HCC1143, HCC1500, HCC1806, hs578T, MDAMB231, and MDAMB468), and BRCA1 -mutated (HCC1937, MDAMB436, SUM149PT, and SUM1315MO2) breast cancers. These cell lines were chosen based on previous reports of their breast cancer subtype, gene expression profile, triple-negative status, and BRCA1 genotype (26) (27) (28) (29) . The basal-like breast cancer cell lines used in this study have all been reported to be triple-negative without BRCA1 mutations. We confirmed triple-negative and BRCA1 status by immunoblotting for estrogen receptor, progesterone receptor, and HER2 expression and for BRCA1 nuclear expression, respectively (data not shown). We then analyzed this panel of human breast cell lines for H 2 O 2 sensitivity as an indicator of response to ODD. Cells were treated with increasing concentrations of H 2 O 2 for 72 hours and analyzed for sensitivity by MTT assay. Based on the average IC 50 value for each cell line within a subtype (Table 1) , the basal-like and BRCA1-mutated breast cancer cell lines were significantly more sensitive to H 2 O 2 than the normal-like breast cell lines (P = 0.0003 and P = 0.009, respectively), whereas the luminal breast cancer cell lines were not significantly more sensitive to H 2 O 2 than the normal-like breast cell lines (P = 0.1; Fig. 1A) . Likewise, the basal-like and BRCA1-mutated cell lines were similarly sensitive to H 2 O 2 (P = 0.6), and were both significantly more sensitive to H 2 O 2 than the luminal breast cancer cell lines (P = 0.0003 and P = 0.006, respectively; Fig. 1A ).
Sensitivity to ODD in the presence of BRCA1 deficiency. Table 1 . Gray shaded area, the range of IC 50 values, dashed line, the average IC 50 value, and solid line, the median IC 50 value for each subtype. B, analysis of H 2 O 2 sensitivity by MTT assay in BRCA1 +/+ (.) and BRCA1 À/À ( w ) MMECs. The graph illustrates sensitivity following treatment with increasing concentrations of oxidizing agent. The IC 50 concentrations as determined by interpolation from the dose-response curves are indicated for each cell line. C, basal levels of ODD in BRCA1 +/+ and BRCA1 À/À MMECs. ODD was measured by the alkaline comet assay modified for detection of oxidized bases using logarithmically growing cells. ODD was visualized by fluorescent microscopy (top ), and quantified by measuring the percentage of DNA in comet tails using comet software (bottom ). White bars, typical comet tails.
BER activity among subtypes of breast cancer. Given that ODD is typically repaired by BER, we examined BER activity in breast cancer cell lines of different subtypes. To do so, we developed a cell-based BER assay ( Supplementary Fig. S1 ) that maintains an intact cellular environment and eliminates the need for exogenous agents that often induce nonspecific damage to DNA, protein, and lipids. The BER assay consists of three basic steps (a) oxidatively damaging a GFP-reporter gene, (b) adenoviralmediated gene transfer for delivery of the damaged GFP-reporter gene into living cells, and (c) host-cell reactivation, which allows for repair of the oxidatively-damaged reporter gene and expression of GFP. The GFP reporter gene was damaged ex vivo using photodynamic treatment, a known method for inducing ODD (30) , to levels that preclude transcription of the GFP gene and thereby prevent expression of the GFP protein. Adenovirus was chosen due to its robust infection efficiency, ability to infect dividing and nondividing cells, and ease of delivery. Following sufficient time for repair and expression of the ODD-induced GFP reporter gene by the host-cell, we measured fluorescence. A green fluorescent signal indicated expression of the GFP reporter gene, which occurred if the GFP coding sequence that contained ODD was repaired by BER.
We analyzed the BER activity of several breast cancer cell lines using this novel cell-based assay. The cell lines were chosen to represent the different subtypes of breast cancer (luminal: BT474, MCF7; basal-like: HCC38, HCC1143, and MDAMB468; BRCA1-mutated: SUM149PT) and exhibited efficient viral infectivity, i.e., a requirement for the BER assay. The basal-like and BRCA1-mutated cell lines similarly showed a decrease in expression of GFP at 24 hours following infection with the oxidatively damaged GFP reporter gene compared with the undamaged control, whereas the luminal breast cancer cell lines showed little decrease in GFP expression ( Fig. 2A) . Therefore, basal-like and BRCA1-mutated cell lines are defective in BER.
We next asked whether the sensitivity to H 2 O 2 correlated with GFP expression in the BER assay. When the average IC 50 value for H 2 O 2 sensitivity was plotted against the difference in GFP expression between the damaged and undamaged conditions for each of the representative cell lines, we found a near-linear relationship between the two variables following regression analysis (r 2 = 0.94; Fig. 2B ), and by calculation of the Pearson coefficient, a positive correlation between the average H 2 O 2 IC 50 value and GFP expression (r = 0.96), indicating that greater sensitivity to H 2 O 2 corresponds to decreased BER.
BER activity in the presence of altered BRCA1. To further examine the role of BRCA1 in BER, we transfected the BRCA1-mutated SUM149PT breast cancer cell line with wild-type BRCA1, and using the BER assay, we found that cells expressing wild-type BRCA1 showed greater host-cell reactivation of the GFP reporter gene than the cells containing mutant BRCA1. Figure 2C illustrates an approximate 4-fold increase in BER activity. We also transfected the BRCA1 wild-type MDAMB361 breast cancer cell line with Western blot illustrates nuclear expression of wild-type BRCA1 (top ). TATA-binding protein (TBP ) was used as a nuclear loading control. Columns, expression of GFP as determined by the BER assay (bottom ), which was quantified using a fluorescent plate reader and calculated relative to the vector control. D, BER activity in the MDAMB361 breast cancer cell line (wild-type BRCA1) transfected with shRNA to BRCA1. Expression of BRCA1 (top ) and GFP (bottom ) were determined as in C .
shRNA to BRCA1, and found that shRNA knocked down the expression of BRCA1 and decreased host-cell reactivation relative to cells containing nontargeting control shRNA. Knockdown of BRCA1 corresponded to an f28% decrease in BER activity (Fig. 2D) . Taken together, BRCA1 functions in BER.
Effect of a BER defect on ODD. To evaluate the response to oxidative stress in the presence of a known BER defect, we generated isogenic cell lines stably expressing shRNA to hOGG1, which is the initiating enzyme for the repair of ODD (8-oxoguanine lesions) by BER. We selected two different cell lines (MCF7shOGG1-A and MCF7shOGG1-B) that knocked down the expression of hOGG1 to 0.21 F 0.09 and 0.51 F 0.5 relative to that of a shRNA control cell line (MCF7shCTRL), respectively (A, P = 0.00009; B, P = 0.008; Fig. 3A) .
We then analyzed H 2 O 2 sensitivity by MTT assay. By comparing IC 50 values, MCF7shOGG1-A and MCF7shOGG1-B cell lines were 3-fold and 2.4-fold more sensitive to H 2 O 2 compared with MCF7shCTRL, respectively (A, P = 0.01; B, P = 0.04; Fig. 3B ). MMS methylating agents lead to DNA base alterations that are also repaired by BER, but MMS-mediated BER does not use the ODDspecific glycosylase hOGG1. Therefore, to determine specificity for ODD, we analyzed hOGG1 knockdown and control cell lines for MMS sensitivity by MTT assay. MCF7shOGG1-A, MCF7shOGG1-B, and MCF7shCTRL cell lines were similarly sensitive to MMS (A, P = 0.5; B, P = 0.3; Fig. 3C ).
Finally, we analyzed repair activity using the BER assay. MCF7shOGG1-A and MCF7shOGG1-B decreased host-cell reactivation of the GFP reporter gene to 0.36 F 0.04 and 0.65 F 0.13 relative to that of MCF7shCTRL, respectively (A, P = 0.00001; B, P = 0.01; Fig. 3D ). These results show that the expression of hOGG1 affects H 2 O 2 sensitivity and BER activity, and indicate an ODDspecific response.
PARP inhibitor sensitivity in BER-compromised cells. To assess whether the sensitivity to PARP inhibitors observed in BRCA1-mutant cells may be due to their defective BER activity, we subjected the hOGG1 knockdown and control cell lines to increasing concentrations of a PARP inhibitor, IQD, and tested their sensitivity after 96 hours by MTT assay. MCF7shOGG1-A (140 Amol/L) and MCF7shOGG1-B (80 Amol/L) cell lines were 5-fold to 10-fold more sensitive to IQD compared with the MCF7shCTRL cell line (800 Amol/L; Fig. 4A Regression analysis of the data showed a near-linear relationship between the two variables (r 2 = 0.96), with a clear distinction between the data points of the basal-like and luminal cell lines (Fig. 4C) , and calculation of the Pearson coefficient identified a positive correlation between sensitivity to PARP inhibitor and H 2 O 2 (r = 0.98). These results show that the deficiency in Columns, average IC 50 value F SE from at least three independent experiments. D, BER activity in shOGG1-expressing cell lines. Columns, average GFP expression F SE from at least three independent experiments as determined by the BER assay (**, P < 0.01; *, P < 0.05).
hOGG1-mediated BER conferred cellular sensitivity to inhibition of PARP, and that a deficiency in BER contributed at least in part to a selective response of the basal-like subtype of breast cancer cells to treatment with a PARP inhibitor.
Discussion
Currently, limited information exists regarding the specific mechanisms that initiate and maintain BRCA1-mutated cancers, and even less is known for the similarly aggressive but more common basal-like subtype of breast cancer. Defects in response to DNA damage and in DNA repair are central to the pathogenesis of human malignancies (31) . The BRCA1 cancer susceptibility gene is known to affect multiple DNA repair processes, including homologous recombination, nonhomologous end-joining, and nucleotide excision repair (16, 17, 32) . However, whether defects in these processes alone are causative for carcinogenesis remains unclear, and whether deficiencies in DNA repair pathways exist in basal-like breast cancers with a similar phenotype, but without mutations in BRCA1, are unknown. We found that repair of ODD by BER, which when aberrant leads to breast carcinogenesis, is defective in triple-negative breast cancer cells and (at least for BRCA1-mutated breast cancers) involves a function by BRCA1. Furthermore, defective repair of ODD by BER conferred sensitivity to inhibition of PARP, a DNA repair enzyme. Therefore, defects in DNA damage response pathways involved in breast carcinogenesis of triple-negative breast cancers, such as that for BER, may serve as targets for therapy and thus be exploited for therapeutic purposes.
We identified for the first time a defect in the repair of ODD by BER in triple-negative breast cancer cells. Basal-like and BRCA1-mutated cell lines showed greater sensitivity to H 2 O 2 and decreased repair of an ODD-induced GFP reporter gene using a novel cellbased BER assay compared with the normal-like and luminal breast cancer cell lines ( Figs. 1A and 2A) . Given that ODD has been implicated in the initiation and progression of breast cancer (33) (34) (35) (36) , basal-like and BRCA1-mutated breast cancers may share similar mechanisms of carcinogenesis. We observed some variability in sensitivity to ODD among the basallike breast cancer cell lines (Table 1; Fig. 1A ). This variability was expected due to the use of a set of heterogeneous cell lines needed to represent the complicated and variable genetic backgrounds of basal-like breast tumors, but was inconsequential as evidenced by the highly statistically significant difference in H 2 O 2 sensitivity when compared with the normal-like (P = 0.0003) and luminal (P = 0.0003) cell lines. The variability may also be due to redundancy within the BER pathway or crosstalk among the different repair pathways that exist to preserve genomic stability. For example, the MDAMB468 cell line (H 2 O 2 IC 50 = 333 Amol/L) expresses wild-type BRCA1 at higher levels than the HCC38 cell line (H 2 O 2 IC 50 = 20 Amol/L; data not shown), and thus may be able to better manage H 2 O 2 -induced ODD. Similar to basal-like and BRCA1-mutated breast cancer cells, BER-proficient cells expressing two different shRNA to hOGG1, the initiating glycosylase for 8-oxoguanine DNA lesions in mammalian cells, showed an increased sensitivity to H 2 O 2 and reduced repair of the ODD- Table 2 induced GFP reporter gene compared with control cells (Fig. 3A, B , and D). Our finding that hOGG1 knockdown and control cells were similarly sensitive to methylating agent MMS (Fig. 3C ) supports a defect specific for repair of ODD in hOGG1 knockdown cells. Taken together, the triple-negative breast cancer cell lines respond to oxidative stress as do cells deficient in an important enzyme involved in the repair of ODD by BER. The 2-fold to 3-fold difference in H 2 O 2 sensitivity between hOGG1 knockdown and control cells (Fig. 3B ) compared with the up to 75-fold difference between the basal-like and normal-like or luminal cells (Table 1) may also be due to redundancy and crosstalk of the different repair pathways, such that the parental cell line of the hOGG1 knockdown cells is a luminal cell line with wild-type BRCA1 and thus may better respond to ODD.
We also showed that BRCA1 plays a role in the repair of ODD by BER and this role likely relates to its function as a tumor suppressor. Consistent with greater H 2 O 2 sensitivity and diminished BER activity in human breast cancer cells with mutant BRCA1, MMECs null for BRCA1 were also more sensitive to H 2 O 2 and contained greater basal levels of ODD than the isogenic wildtype MMECs (Fig. 1B and C) . Furthermore, expressing wild-type BRCA1 in a mutant background (Fig. 2C ) resulted in greater repair of the ODD-induced GFP reporter gene, and decreasing expression of BRCA1 in a wild-type background using shRNA (Fig. 2D ) resulted in less repair. Therefore, we found that elevated levels of ODD are due at least in part to defective BER in the presence of aberrant BRCA1. Rodriguez and colleagues observed a greater number of ODD lesions induced by ionizing radiation in lymphoblast-derived cell lines from BRCA1 mutation carriers diagnosed with breast cancer compared with nonmutation carriers without cancer (37) . These data support our finding that BRCA1 plays a role in BER. The exact mechanism by which BRCA1 regulates BER is yet to be determined, but may be similar to that observed for other types of repair, including transcriptional regulation of repair genes or interaction with other repair proteins (16, 17, 32) . It is possible that BRCA1 and p53 act together to regulate ODD because mutations in BRCA1 are often accompanied by mutations in p53 (38) (39) (40) , and all of the observed H 2 O 2 -sensitive and BER-defective cells in this study were mutant or deficient for wild-type p53. Furthermore, p53 regulates hOGG1 expression and enhances BER activity (41) (42) (43) (44) (45) .
We showed that defective BER confers sensitivity to inhibition of PARP. Basal-like, BRCA1-deficient, and hOGG1 knockdown cells were all found to be compromised for BER and to be sensitive to the IQD PARP inhibitor (Figs. 2 and 4A, B) . Sensitivity to PARP inhibition is thus not limited to BRCA1 and BRCA2-mutated cancers, but is characteristic of the larger subgroup of basal-like breast cancers. The sensitivity of BRCA1-and BRCA2-mutated tumors to PARP inhibitors has been assumed to be due to a synthetic-lethal mechanism based on the function of BRCA1 and BRCA2 in homologous recombination (46) . In this scenario, inhibition of PARP precludes the repair of single-strand break intermediates of the BER pathway, which upon replication, convert to double-strand breaks, thereby sensitizing cells with compromised double-strand break repair (i.e., BRCA1-deficient cells). However, our finding that cells deficient in hOGG1 were more sensitive to IQD compared with the isogenic control (Fig. 4A) indicates a broader mechanism in determining sensitivity to PARP inhibition. Basal-like or BRCA1-deficient cells may also be more sensitive to these agents due to further inhibition of already compromised BER activity. In addition, BRCA1-deficient cells may be more sensitive to PARP inhibition due to an inability to perform nucleotide excision repair, which sometimes compensates for BER in the presence of excessive ODD (17, 47) . Therefore, the effect of PARP inhibition in triple-negative breast cancer cells likely encompasses the attenuation of multiple DNA repair pathways, resulting in increased susceptibility to DNA damage.
We found that H 2 O 2 sensitivity associated with elevated levels of ODD in BRCA1-mutated cells (Fig. 1C) , and that H 2 O 2 sensitivity correlated with BER activity in the different subtypes of breast cancer cell lines (Fig. 2B ). Taken together with our data showing defective repair of ODD by BER in the presence of deficient or mutated BRCA1 and in basal-like breast cancer cells (Table 1, Figs. 1A, B and 2A, C, D), our findings indicate that BRCA1-mutated or the similar basal-like breast cancer cells are more sensitive to H 2 O 2 due to greater levels of ODD that are left unrepaired as a result of compromised BER. This defect in repair of ODD by BER may be causative for carcinogenesis, and may also be exploited for therapeutic benefit. First, our finding that selective inhibition of BER by knockdown of hOGG1 conferred sensitivity to PARP inhibition identified the BER pathway as a potential therapeutic target. Basal-like or BRCA1-mutated breast cancers currently need novel approaches for targeted therapy. Therefore, our data warrant future studies that will analyze the use of other inhibitors of the BER pathway for treatment of these triple-negative cancers. Alternatively, combination therapies that target PARP and other BER proteins may be effective in the treatment of luminal breast cancers. Second, we found that H 2 O 2 sensitivity correlated with IQD sensitivity (Fig. 4C) . Comparison of these sensitivities revealed two distinct populations, an H 2 O 2 /IQD-sensitive population representing the basal-like cell lines and a relatively insensitive H 2 O 2 /IQD population representing the luminal cell lines (Fig. 4C) . Therefore, response to ODD, including H 2 O 2 sensitivity and/or BER, may predict sensitivity to PARP inhibition, specifically for the basal-like subtype of breast cancer.
In summary, we found using a novel assay for in vivo BER activity that triple-negative breast cancer cells are deficient in BER of ODD, and that this defect may be attributed, at least in part, to a novel role for BRCA1 in the BER pathway. We also found that the BER defect contributes to a newly described mechanism for sensitivity to PARP inhibition. The current study describes a common carcinogenic event for basal-like and BRCA1-mutated cancers with therapeutic potential, including the proposition of novel targets for future therapeutic strategies and the ability to select triple-negative cancers for treatment with PARP inhibitor. Our data have additional clinical implications. First, our finding that BRCA1 may function in ODD-mediated carcinogenesis will be useful for determining novel strategies for cancer prevention, which is particularly important for carriers of mutations in BRCA1 who have an increased risk for developing breast and ovarian cancer (48, 49) . Second, our in vivo BER assay may be useful for predicting the therapeutic effectiveness of PARP inhibitors in other tumor types. Currently, we are adapting this methodology for use in primary cancer cells obtained from patients on clinical trials.
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